Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vivani Medical, Inc.EYES · Entity 6636 | VP Clinical Affairs | January 04, 2018 | January 09, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vivani Medical, Inc.
Report date January 04, 2018 · Filed January 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2028-01-04 | Direct | 65,000 |
Reported balance
After 2018-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-04 · Grant · Acquired 65,000 · Balance 65,000 F6: Not Applicable F2: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 4, 2018 (the "Vesting Commencement Date") and 6.25% of the total number of shares shall vest each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2027-01-03 | Direct | 228,190 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 228,190 F3: Options vest over a four year term of which one-fourth vest on the Date Exercisable, with the remaining options vesting quarterly over three years thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2026-01-21 | Direct | 11,513 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 11,513 F3: Options vest over a four year term of which one-fourth vest on the Date Exercisable, with the remaining options vesting quarterly over three years thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2018-11-01 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 200,000 F4: Options vest in 5 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2019-02-01 | Direct | 5,081 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 5,081 F4: Options vest in 5 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2019-05-01 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 10,000 F4: Options vest in 5 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2020-02-01 | Direct | 14,475 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 14,475 F4: Options vest in 5 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2020-06-01 | Direct | 2,125 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 2,125 F4: Options vest in 5 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2020-12-01 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 25,000 F5: Options vest in 4 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2021-03-01 | Direct | 6,650 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 6,650 F5: Options vest in 4 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2022-03-01 | Direct | 7,750 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 7,750 F5: Options vest in 4 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2024-04-01 | Direct | 10,937 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 10,937 F5: Options vest in 4 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.00 · Expires 2024-09-26 | Direct | 51,009 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 51,009 F5: Options vest in 4 yearly increments starting with the Date Exercisable |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.09 · Expires 2025-03-25 | Direct | 6,250 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 6,250 F5: Options vest in 4 yearly increments starting with the Date Exercisable |
| Common StockSEC Table I · non-derivative | Direct | 23,484 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 23,484 F1: Shares acquired as part of scheduled ESPP purchases. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2022-03-14 | Direct | 3,366 |
Reported balance
Holding disclosure · report date 2018-01-04 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,366 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired as part of scheduled ESPP purchases.
F2: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 4, 2018 (the "Vesting Commencement Date") and 6.25% of the total number of shares shall vest each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.
F3: Options vest over a four year term of which one-fourth vest on the Date Exercisable, with the remaining options vesting quarterly over three years thereafter.
F4: Options vest in 5 yearly increments starting with the Date Exercisable
F5: Options vest in 4 yearly increments starting with the Date Exercisable
F6: Not Applicable
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2018 Filed Jan 9, 2018 00:32 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $2.06 | Not disclosed |
DisclosureSEC source: 0001615774-18-000194 · s108661_form4.xml · derivative · entry 2 Cosendai Gregoire · CIK 0001625468 · VP Clinical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-01-04 F6 · price: Not Applicable F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 4, 2018 (the "Vesting Commencement Date") and 6.25% of the total number of shares shall vest each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 21:53 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantWarrant to Purchase Common Stock · Derivative | 3,366 | Not disclosed Strike: $1.47 | Not disclosed |
DisclosureSEC source: 0001615774-17-001106 · s105585_form4.xml · derivative · entry 2 Cosendai Gregoire · CIK 0001625468 · VP of European Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,366 Underlying: Common Stock · 3,366 shares Expires 2022-03-14 F1 · shares: Common stock and warrants reported on this Form 4 pursuant to an exercise of subscription rights previously distributed by the Company to all holders of the Company's common stock. Each stockholder received a right to invest $0.47 for every share held of record on February 10, 2017, the record date, to purchase units consisting of one share of common stock and one warrant to purchase one share of common stock. The final allocation numbers of units were distributed on March 14, 2017. F1 · price: Common stock and warrants reported on this Form 4 pursuant to an exercise of subscription rights previously distributed by the Company to all holders of the Company's common stock. Each stockholder received a right to invest $0.47 for every share held of record on February 10, 2017, the record date, to purchase units consisting of one share of common stock and one warrant to purchase one share of common stock. The final allocation numbers of units were distributed on March 14, 2017. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 21:53 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantCommon Stock | 3,366 | $1.47 | $4,948.02 |
DisclosureSEC source: 0001615774-17-001106 · s105585_form4.xml · nonDerivative · entry 1 Cosendai Gregoire · CIK 0001625468 · VP of European Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,395 F1 · balance_after: Common stock and warrants reported on this Form 4 pursuant to an exercise of subscription rights previously distributed by the Company to all holders of the Company's common stock. Each stockholder received a right to invest $0.47 for every share held of record on February 10, 2017, the record date, to purchase units consisting of one share of common stock and one warrant to purchase one share of common stock. The final allocation numbers of units were distributed on March 14, 2017. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 01:09 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 228,190 | Not disclosed Strike: $1.97 | Not disclosed |
DisclosureSEC source: 0001615774-17-000050 · s105063_form4.xml · derivative · entry 2 Cosendai Gregoire · CIK 0001625468 · VP of European Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,190 Underlying: Common Stock · 228,190 shares Expires 2027-01-03 F2 · shares: Options to purchase 228,190 shares of the Company's common stock were granted to Mr. Cosendai under the Company's 2011 Equity Incentive Plan. F6 · price: Not Applicable F3 · derivative.exercise_date: Options vest over a four year term of which one-fourth vest on the Date Exercisable, with the remaining options vesting quarterly over three years thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.